摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-氟-3-羟基苯基)乙酸 | 31338-68-8

中文名称
(4-氟-3-羟基苯基)乙酸
中文别名
4-氟-3-羟基苯乙酸
英文名称
4-fluoro-3-hydroxyphenylacetic acid
英文别名
2-(4-fluoro-3-hydroxyphenyl)acetic acid
(4-氟-3-羟基苯基)乙酸化学式
CAS
31338-68-8
化学式
C8H7FO3
mdl
MFCD09263485
分子量
170.14
InChiKey
SRWPTQILYBZQDE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    332.6±27.0 °C(Predicted)
  • 密度:
    1.423±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2918290000

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds
    申请人:AstraZeneca AB
    公开号:US08148572B2
    公开(公告)日:2012-04-03
    The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    该发明涉及取代苯乙酸作为治疗呼吸系统疾病有用的药物化合物,包含它们的制药组合物以及其制备过程。
  • Peg-based adhesive phenylic derivatives and methods of synthesis and use
    申请人:MURPHY John L.
    公开号:US20160032047A1
    公开(公告)日:2016-02-04
    The invention provides compositions that use phenylic derivatives to provide adhesive properties. Selection of phenylic derivatives with linkers or linking groups, and the linkages between the linkers or linking groups with polyalkylene oxides, provided herein may be configured to control curing time, biodegradation and/or swelling.
    本发明提供了使用苯基衍生物作为黏合剂的组合物。本发明提供了苯基衍生物与连接剂或连接基团的选择,以及连接剂或连接基团与聚烷氧化物之间的连接,可以配置以控制固化时间、生物降解和/或肿胀。
  • Novel Compounds
    申请人:Luker Timothy Jon
    公开号:US20090192163A1
    公开(公告)日:2009-07-30
    The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    本发明涉及取代苯乙酸作为治疗呼吸系统疾病的有用药物化合物、含有它们的药物组合物以及它们的制备方法。
  • FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1535915A1
    公开(公告)日:2005-06-01
    The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.
    本发明提供了一种由式(I)表示的化合物: [其中 R 为任选取代的烃基或任选取代的杂环基,p 为 0、1 或 2,当 p 为 2 时,每个 R 可以相同或不同,R1 为氢原子或任选取代的烃基,R2 为任选取代的芳香基、环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环,X1 是氧原子或硫原子,X2 是键、氧原子或 -S(O)n- (其中 n 是 0、1 或 2),Y 是键、氧原子、-S(O)m-、-R3是氢原子、任选取代的烃基或任选取代的杂环基,m是0、1或2),M1、M2和M3可以相同或不同,各自独立地是键或任选取代的二价脂族烃基、和 M4 是任选取代的二价脂族烃基]或其盐,可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
  • Furan or thiopene derivative and medicinal use thereof
    申请人:Hamamura Kazumasa
    公开号:US20060100261A1
    公开(公告)日:2006-05-11
    The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R 1 is a hydrogen atom or an optionally substituted hydrocarbon group, R 2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X 1 is an oxygen atom or a sulfur atom, X 2 is a bond, an oxygen atom or —S(O) n — (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O) m —, —C(═O)—N(R 3 )— or —N(R 3 )—C(═O)— (R 3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M 1 , M 2 and M 3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M 4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.
    本发明提供了一种由式(I)表示的化合物: [其中 R 为任选取代的烃基或任选取代的杂环基,p 为 0、1 或 2,当 p 为 2 时,每个 R 可以相同或不同,R 1 是氢原子或任选取代的烃基,R 2 是任选取代的芳香基团,环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环,X 1 是氧原子或硫原子,X 2 是键、氧原子或 -S(O) n - 其中 n 为 0、1 或 2),Y 为键、氧原子、-S(O) m -、-C(═O)-N(R 3 )-或-N(R 3 )-C(═O)-(R 3 是氢原子、任选取代的烃基或任选取代的杂环基,且 m 是 0、1 或 2),M 1 , M 2 和 M 3 可以相同或不同,且各自独立地为键或任选取代的二价脂族烃基,以及 M 4 是任选取代的二价脂族烃基]或其盐,可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
查看更多